NCX 6560, a nitric oxide-releasing derivative of atorvastatin, inhibits cholesterol biosynthesis and shows anti-inflammatory and anti-thrombotic properties

European Journal of Pharmacology

Volumn 570, Issue 1-3, 2007, Pages 115-124

  Momi, Stefania ^a   Impagnatiello, Francesco ^b   Guzzetta, Massimiliano ^b   Caracchini, Roberta ^a   Guglielmini, Giuseppe ^a   Olivieri, Rossana ^b   Monopoli, Angela ^b   Gresele, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b NicOx Research Institute   (Italy)

Author keywords

Anti inflammatory; Anti thrombotic; Hyperlipidemia; NCX 6560; Nitric oxide; Platelets

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 (4 FLUOROPHENYL) BETA,DELTA DIHYDROXY 5 (1 METHYLETHYL) 3 PHENYL 4 [(PHENYLAMINO)CARBONYL] 1H PYRROLE 1 HEPTANOIC ACID 4 (NITROOXY)BUTYL ESTER; ADRENALIN; ATORVASTATIN; CHOLESTEROL; COLLAGEN; CYCLIC GMP; DIMER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; ISOSORBIDE MONONITRATE; LIPOPOLYSACCHARIDE; NCX 6560; NITRITE; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG ACTIVITY; DRUG EFFECT; ESCHERICHIA COLI; EX VIVO STUDY; HYPERLIPIDEMIA; IC 50; KNOCKOUT MOUSE; LUNG EMBOLISM; MACROPHAGE; MALE; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SMOOTH MUSCLE FIBER; THROMBOCYTE ADHESION; VASCULAR RING; VASODILATATION; WILD TYPE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICHOLESTEREMIC AGENTS; AORTA, THORACIC; BLOOD PRESSURE; CELL LINE; CHOLESTEROL; CYCLIC GMP; FIBRINOLYTIC AGENTS; HEPTANOIC ACIDS; HYPERLIPIDEMIAS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE DONORS; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; PC12 CELLS; PULMONARY EMBOLISM; PYRROLES; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 34547828238     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.05.014     Document Type: Article

References (40)

1. Baker S.K., and Tarnopolsky M.A. Statin-associated neuromyotoxicity. Drugs Today 41 (2005) 267-293
2. Ballantyne C.M. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction. Am. J. Cardiol. 96 (2005) 14K-19K (discussion 34K-35K)
3. Bellosta S., Paoletti R., and Corsini A. Safety of statins. Focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) III50-III57
4. Chen H., Ikeda U., Shimpo M., Ikeda M., Minota S., and Shimada K. Fluvastatin upregulates inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells. Hypertension 36 (2000) 923-928
5. Chen Y., Panda K., and Stuehr D.J. Control of nitric oxide synthase dimer assembly by a heme-NO-dependent mechanism. Biochemistry 41 (2002) 4618-4625
6. Conde K., Pineda G., Newton R.S., and Fernandez M.L. Hypocholesterolemic effects of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase ihnibitors in guinea pig. Biochem. Pharmacol. 58 (1999) 1209-1219
7. Corsini A., Bernini F., Cighetti G., Soma M., Galli G., and Fumagalli R. Lipophilic β-adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts. Biochem. Pharmacol. 36 (1987) 1901-1906
8. Eissa N.T., Haggerty C.M., Palmer C.D., Patton W., and Moss J. Identification of residues critical for enzymatic activity in the domain encoded by exons 8 and 9 of the human inducible nitric oxide synthase. Am. J. Respir. Cell Mol. Biol. 24 (2001) 616-620
9. Friebe A., Mullershause F., Smolenski A., Walter U., Schultz G., and Koesling D. YC-1 potentiates nitric- and carbon monitrites and nitrateside-induced cyclic GMP effects in human platelets. Mol. Pharmacol. 54 (1998) 962-967
10. Gauthier T.W., Scalia R., Murohara T., Guo J.P., and Lefer A.M. Nitric oxide protects against leukocyte-endothelium interactions in the early stages of hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 15 (1995) 1652-1659
11. Goto T., Ohnomi S., Khedara A., Kato N., Ogawa H., and Yanagita T. Feeding the nitric oxide synthase inhibitor L-N (omega) nitroarginine elevates serum very low density lipoprotein and hepatic trilygeride synthesis in rats. J. Nutr. Biochem. 10 (1999) 274-278
12. Gotto Jr. A.M. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am. J. Cardiol. 96 (2005) 34F-38F
13. Harangi M., Seres I., Varga Z., Emri G., Szilvassy Z., Paragh G., and Remenyik E. Atorvastatin effect on high density lipoprotein-associated paraoxonase activity and oxidative DNA damage. Eur. J. Clin. Pharmacol. 60 (2004) 685-691
14. Huang P.L., Huang Z., Mashimo H., Bloch K.D., Moskowitz M.A., Bevan J.A., and Fishman M.C. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 (1995) 239-242
15. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., and Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 9265-9269
16. Ignarro L.J., Buga G.M., Wei L.H., Bauer P.M., Wu G., and Del Soldato P. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4202-4208
17. Izzat N.N., Deshazer M.E., and Loose-Mitchell D.S. New molecular targets for cholesterol-lowering therapy. J. Pharmacol. Exp. Ther. 293 (2000) 315-320
18. Johnson T.P., Baker J.C., Hall D., Jamal S., Palmer W.K., and Emeson E.E. Regression of poloxamer 407-induced atherosclerosis lesions in C57BL/6 mice using atorvastatin. Atherosclerosis 149 (2000) 303-313
19. Khedara A., Goto T., Kayashita J., and Kato N. Hypercholesterolemic effect in rats of a dietary addition of the nitric oxide synthase inhibitor, L-N omega nitroarginine, by less synthesis of bile acids. Biosci. Biotechnol. Biochem. 62 (1998) 773-777
20. Krause B.R., and Newton R.S. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis 117 (1995) 237-244
21. Law M.R., Wald N., and Rudnicka A.R. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Br. Med. J. 326 (2003) 1423
22. Li D., Hayden E.Y., Panda K., Stuehr D.J., Deng H., Rousseau D.L., and Yeh S.R. Regulation of the monomer-dimer equilibrium in inducible nitric oxide synthase by NO. J. Biol. Chem. 281 (2006) 8197-8204
23. Manabe T., Yamamoto A., Satoh K., and Ichihara K. Tolerance to nitroglycerin induced by isosorbide-5-mononitrate infusion in vivo. Biol. Pharm. Bull. 24 (2001) 1370-1372
24. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., and Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 71 (1988) 1366-1374
25. Momi S., Emerson M., Paul W., Leone M., Mezzasoma A.M., Del Soldato P., Page C.P., and Gresele P. Prevention of pulmonary thromboembolism by NCX 4016, a nitric oxide-releasing aspirin. Eur. J. Pharmacol. 397 (2000) 177-185
26. Momi S., Pitchford S.C., Alberti P.F., Minuz P., Del Soldato P., and Gresele P. Nitroaspirin plus clopidogrel versus aspirin plus clopidogrel against platelet thromboembolism and intima thickening in mice. Thromb. Haemost. 92 (2005) 535-543
27. Moncada S., Rees D.D., Schulz R., and Palmer R.M.J. Development and mechanism of a specific supersensitivity to nitrovasodilators after inhibition of vascular nitric oxide synthesis in vivo. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 2166-2170
28. Muscarà M.N., Lovren F., McKnight W., Dicay M., Del Soldato P., Triggle C.R., and Wallace J.L. Vasorelaxant effects of a nitric oxide-releasing aspirin derivative in normotensive and hypertensive rats. Brit. J. Pharmacol. 133 (2001) 1314-1322
29. Ongini E., Impagnatiello F., Bonazzi A., Guzzetta M., Govoni M., Monopoli A., Del Soldato P., and Ignarro L.J. Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and anti-inflammatory properties. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 8497-8502
30. Presotto C., Miglietta D., Olivieri R., and Monopoli A. The nitropravastatin derivative, NCX 6550, improves endothelial dysfunction in spontaneously hypertensive rats. Circulation 112 Suppl II (2005) 17
31. Radomski M.W., Palmer R.M., and Moncada S. An l-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. U. S. A. 87 (1990) 5193-5197
32. Ronchetti D., Impagnatiello F., Guzzetta M., Gasparini L., Borgatti M., Gambari R., and Ongini E. Modulation of iNOS expression by a nitric oxide-releasing derivative of the natural antioxidant ferulic acid in activated RAW 264.7 macrophages. Eur. J. Pharmacol. 532 (2006) 162-169
33. Rossiello M.R., Momi S., Caracchini R., Giannini S., Guglielmini G., Monopoli A., Ongini E., Semeraro N., Colucci M., and Gresele P. A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J. Thromb. Haemost. 3 (2005) 2554-2562
34. Schwarz M., Meade G., Stoll P., Ylanne J., Bassler N., Chen Y.C., Hagemeyer C.E., Ahrens I., Moran N., Kenny D., Fitzgerald D., Bode C., and Peter K. Conformation-specific blockade of the integrin GPIIb/IIIa: a novel strategy that selectively targets activated platelets. Circ. Res. 99 (2006) 25-33
35. Sixma J.J., de Groot P.G., van Zanten H., and Ijsseldijk M. A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb. Res. 92 (1988) 43-46
36. Steinberg D., and Witztum J.L. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?. Circulation 105 (2002) 2107-2111
37. Takemoto M., and Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutayl coenzyme a reductase inhibitors. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1712-1719
38. Verma S., and Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 (2002) 546-549
39. Voetsch B., Jin R.C., and Loscalzo J. Nitric oxide insufficiency and atherothrombosis. Histochem. Cell Biol. 122 (2004) 353-367
40. Wagner A.H., Schwabe O., and Hecker M. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br. J. Pharmacol. 136 (2002) 143-149